Navigation Links
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Date:5/17/2012

last week of the 12-week, double-blind maintenance phase, as determined by an 11-point pain rating scale or numerical rating scale (NRS; 0='no pain,' 10='pain as bad as you can imagine'). Safety assessments were performed on the open-label and double-blind safety populations (all patients who received greater than or equal to 1 dose of open-label and double-blind treatment, respectively). Treatment-emergent adverse events (TEAEs), defined as any AEs (new or worse in intensity) that occurred after the first intake of study drug during the open-label or double-blind phase, were monitored throughout the study.

In the open-label titration period, 459 patients received one or more doses of tapentadol ER and were included in the open-label safety population. At the start of the 3-week, open-label phase, the majority of patients (87.1 percent) reported severe pain (6 or more on the 11-point NRS) with a mean pain intensity of 7.3. By the end of the open-label phase, the mean pain intensity was reduced to 3.6. Treatment-emergent adverse events (TEAEs) experienced by 10 percent or more of patients during the open-label phase were nausea (24.4 percent), dizziness (17), constipation (11.8) and somnolence (10.7).

A total of 358 patients completed the open-label titration period; 318 were randomized and received one or more dose of study medication (n=152 for placebo, 166 for tapentadol ER).

Following randomization, during the double-blind treatment phase to week 12, pain increased in the placebo group (as demonstrated by the mean change in pain intensity of 1.3), while in the tapentadol ER group, efficacy was maintained, as indicated by the mean change in pain intensity of 0.28. The least-squares mean difference between the tapentadol ER and placebo groups in the change in average pain intensity was -0.95 on the 11-point NRS favoring tapentadol ER (95 percent CI, -1.42 to -0.49; p<0.001, tapentadol ER vs. placebo)(4).

For more details about the s
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
3. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
7. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Marta Rendon, MD, founder of the ... Raton , FL and international key opinion leader in dermatology, ... the United States to attend the international ... Turkey . Here, at this gathering of over 600 ... renowned facial plastic surgery experts from Asia ...
(Date:11/24/2014)...  Surgical Theater, LLC, announced today that their technology ... opening of Europe,s first simulation ... The SuRgical Planner (SRP) and the Surgical Navigation Advanced ... their 3D navigation and augmented reality capabilities in the ... and Chair, Department of Neurosurgery at Mount Sinai Health ...
(Date:11/24/2014)... 24, 2014  Pifflers United Chronic and Invisible ... release of results of a study of ActiPatch®, ... self-management of fibromyalgia pain. The results demonstrated that ... very significant clinically meaningful pain reduction can be ... with fibromyalgia used ActiPatch® for 7 days and ...
Breaking Medicine Technology:Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... Tengion, Inc. (NASDAQ: TNGN ), a ... Vice President Finance and Chief Financial Officer of Tengion, ... Health Care Conference on Wednesday, November 30, 2011, at ... webcast of the presentation can be accessed at ...
... Nov. 21, 2011 /PRNewswire-Asia/ -- Sundia MediTech Company Inc., a ... the company was named one of the 50 best companies ... was announced at an October ceremony in Shanghai. This is ... after it was previously named in 2007 and 2008. ...
Cached Medicine Technology:Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:11/24/2014)... 2014 The Mesothelioma Applied Research ... International Symposium on Malignant Mesothelioma from March 2nd through ... sessions will take place on the campus of the ... a community dinner and an awards ceremony, will be ... cover a range of topics about pleural and peritoneal ...
(Date:11/24/2014)... 2014 A new sports massage ... pain-relief service and massage therapy provider, announced it ... This newest sports massage is a ... between traditional sports massage and ESM is that ... very own "reset button,” and ESM can increase ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 SWAccessControl.com ... locks. As a matter of fact, the company is a ... its brand new magnetic locks are available at discounted prices, ... our new range of magnetic locks. This time, all of ... are popular at home and abroad, so I have confidence ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... put the outbreak in doubt. The mystery began Sept. ... cough, typically heralded by a runny// nose, sneezing, slight fever, ... ,Then in last September through early November, about three ... other symptoms suggesting that they, too, were stricken with the ...
... groups, with relatively little genetic differentiation among the people from ... study. ,Although the study used participants that may ... suggest that the frequencies of many genetic variants are distinctive ... Indian American scientist who led the study said. ...
... that neural stem cells will eventually be useful for ... and multiple sclerosis. But there may also be another ... cells. ,A Perspective article in PLoS Medic ine, ... discusses a new study in mice, published in the ...
... Drug Administration (FDA) will release its approval for consumption of ... ,Two federal scientists, Larisa Rudenko and John C. Matheson. ... milk of cloned animals and their offspring. “On no basis ... from normal animals,” they say. ,A formal recommendation ...
... was 14 months old that left her gasping for breath.// ... to trigger an allergic reaction in people allergic to it. ... a landmark experiment that set to discover-'Could eating tiny amounts ... bodies to overcome severe food allergies?' ,Preliminary results ...
... children may have a shorter life span than those with few ... new study.// ,Researchers led by Dustin Penn and Ken Smith ... living in Utah between 1860 and 1985, who bore a total ... an average of eight children each, but family size ranged from ...
Cached Medicine News:Health News:Indians Make One Major Human Race: US Study 2Health News:Is Your Child Allergic To Peanuts? 2
... that need an advanced ... Vision,Premier Holter System provides ... Vision Premier system,adds expanded ... comprehensive list of diagnostic,codes ...
... EK-10 single-channel,electrocardiograph features a ... keypad. It provides the,necessary ... quick and,accurate diagnosis. The ... a built in handle ...
... three contrast levels (high, 9.5 % and 6%) ... test is designed to detect very subtle changes ... evaluation or due to refractive surgery. The upper ... contrast and acuity levels as the lower two ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: